Targeting the Tumor Microenvironment in Patients with AIDS-Associated EBV+ Diffuse Large B Cell Lymphoma

  • Pollock, Raphael Etomar (PI)
  • Alder, Hansjuerg (CoPI)
  • Alinari, Lapo (CoPI)
  • Andersen, Barbara Lee (CoPI)
  • Baker, Sharyn (CoPI)
  • Balcerzak, S. P. (CoPI)
  • Basso, Kari B. (CoPI)
  • Bennett, Chad E. (CoPI)
  • Bloomfield, Clara Derber (CoPI)
  • Breueggemeier, Robert W. (CoPI)
  • Brueggemeier, Robert Wayne (CoPI)
  • Bruggemeier, Robert W. (CoPI)
  • Burry, Richard Wilson (CoPI)
  • Byrd, John C. (CoPI)
  • Caligiuri, Michael A. (CoPI)
  • Carbone, David Paul (CoPI)
  • Carson, William Edgar (CoPI)
  • Chalmers, Jeffrey John (CoPI)
  • Chan, Kenneth Kin-Hing (CoPI)
  • Clinton, Steven K. (CoPI)
  • Cohn, David E. (CoPI)
  • Coombes, Kevin (CoPI)
  • Croce, Carlo Maria (CoPI)
  • Cschuller, David (CoPI)
  • Yohn, David S. (CoPI)
  • de la Chapelle, Albert (CoPI)
  • Devine, Steven M. (CoPI)
  • Mardis, Elaine (CoPI)
  • Farag, Sherif S. (CoPI)
  • Fernandez, Soledad A. (CoPI)
  • Freitas, Michael Alan (CoPI)
  • Gams, Richard (CoPI)
  • Gosky, David M. (CoPI)
  • Grever, Michael Rhodes (CoPI)
  • Doll, Heather Lynn (CoPI)
  • Heerema, Nyla A. (CoPI)
  • Jackson, Rebecca Dorothy (CoPI)
  • Jarjoura, David (CoPI)
  • Jewell, Scott D. (CoPI)
  • Kirschner, Lawrence S. (CoPI)
  • Kolattukudy, P. E. (CoPI)
  • Kuppusamy, Periannan (CoPI)
  • Kusewitt, Donna F. (CoPI)
  • La Perle, Krista Marie Dubray (CoPI)
  • Lucas, David Matthew (CoPI)
  • Marcucci, Guido (CoPI)
  • Milo, G. E. (CoPI)
  • Minton, John P. (CoPI)
  • Mishra, Pravin K. (CoPI)
  • Mull, Lawrence (CoPI)
  • Naughton, Michelle (CoPI)
  • O'dorisio, Sue M. (CoPI)
  • Ostrowski, Michael C. (CoPI)
  • Otterson, Gregory A. (CoPI)
  • Parvin, Jeffrey (CoPI)
  • Paskett, Electra Diane (CoPI)
  • Peterson, Blake (CoPI)
  • Phelps, A Mitchell (CoPI)
  • Plass, Christoph (CoPI)
  • Powell, Kimerly Ann (CoPI)
  • Ramaswamy, Bhuvaneswari (CoPI)
  • Reiter, Paul L. (CoPI)
  • Ringel, Matthew David (CoPI)
  • Robertson, Fredika M. (CoPI)
  • Robinson, John Mitchell (CoPI)
  • Ruymann, Frederick B. (CoPI)
  • Raval, Raju R.R (CoPI)
  • Garzon, Ramiro R (CoPI)
  • Baiocchi, Robert A. (CoPI)
  • Schaaf, Larry Joe (CoPI)
  • Schuller, David Edward (CoPI)
  • Schwartz, Steven Jay (CoPI)
  • Shapiro, Charles Louis (CoPI)
  • Single, Nancy Ann (CoPI)
  • Slater, Michael D. (CoPI)
  • Lemeshow, Stanley Alan (CoPI)
  • Staubus, A. E. (CoPI)
  • Stephens, Ralph E. (CoPI)
  • Stoner, Gary D. (CoPI)
  • Stoodley, Paul (CoPI)
  • Symer, David E. (CoPI)
  • Thomas, James P. (CoPI)
  • Toland, Amanda E. (CoPI)
  • Tomie, David L. (CoPI)
  • Trewyn, R. W. (CoPI)
  • Tsai, Ming Daw (CoPI)
  • Young, Donn C. (CoPI)
  • Young, Anthony P. (CoPI)
  • Zwilling, Bruce S. (CoPI)
  • Li, Zihai Z (CoPI)

Project Details

Description

PROJECT SUMMARY The Ohio State University Comprehensive Cancer Center (OSUCCC) is in its 44th year as an NCI-designated comprehensive cancer center, having received an “exceptional” overall merit descriptor in its last two reviews in 2010 and 2015, and is requesting continued federal support for the next five years. The OSUCCC mission remains to reduce cancer morbidity and mortality through basic, population, translational and clinical research. Through thoughtful strategic planning, attention to the cancer burden in the catchment area (the state of Ohio), effective organizational capabilities and targeted investment, the Director and his Senior Leadership team will enable the OSUCCC to advance collaborative cancer research with local, national, and global partners on initiatives of the highest priority to the OSUCCC. The 293 full and introductory members are currently served by 16 full and two developing shared resources and are distributed among our five Research Programs: Cancer Biology (formerly Molecular Biology and Cancer Genetics), Cancer Control, Leukemia Research, Molecular Carcinogenesis and Chemoprevention and Translational Therapeutics. The OSUCCC fosters collaborative basic research and implements strategies that advance and translate early discovery into clinical and population-based research and addresses the needs of our catchment area through research, engagement, and outreach, from etiology through prevention, treatment and survivorship regarding the major cancers afflicting our catchment area population. The OSUCCC trains the next generation of cancer-focused scientists and clinicians through new and established programs focused on integrating training for collaborative research efforts. Under the leadership of a new Director, Raphael Pollock, MD, PhD, The OSUCCC supports innovative research efforts within four strategic planning priorities: immuno-oncology, cancer engineering, translational genomics and cancer prevention and survivorship. Since the last CCSG competitive renewal, the OSUCCC has shown significant growth demonstrated by: 1) the recruitment of 108 basic, population, and translational science faculty who are OSUCCC members; 2) the addition of 94,647 ft2 research and administrative space under the full control of the OSUCCC Director; 3) a 16% increase in direct cancer-related funding to $75.4M, with $44.3M coming from the NCI; 4) accrual of 14,996 patients to interventional clinical trials (5,648 accruals to therapeutic trials); 5) increased collaborative and impactful research demonstrated by 3,477 peer-reviewed publications in which 74% of manuscripts are multi-institutional and 85% are collaborative (i.e., inter-, intra-programmatic or multi- institutional); 497 are published in journals with an impact factor >10; 6) the addition of two new shared resources at an institutional investment of $1.3M; and 7) preclinical and clinical development of an FDA approved drug which has changed the treatment for CLL and other blood cancers. With new recruits and strong institutional and philanthropic support in place, the OSUCCC is building upon the momentum and poised in the next five years to take significant steps toward achieving our mission and our broad vision of living in a cancer-free world.
StatusFinished
Effective start/end date07/1/8511/30/24

Funding

  • National Cancer Institute: $50,000.00
  • National Cancer Institute: $139,874.00
  • National Cancer Institute: $239,232.00
  • National Cancer Institute: $4,582,303.00
  • National Cancer Institute: $60,126.00
  • National Cancer Institute: $31,250.00
  • National Cancer Institute: $49,250.00
  • National Cancer Institute: $115,001.00
  • National Cancer Institute: $3,700,000.00
  • National Cancer Institute: $200,000.00
  • National Cancer Institute: $5,040,816.00
  • National Cancer Institute: $89,606.00
  • National Cancer Institute: $5,040,816.00
  • National Cancer Institute: $59,999.00
  • National Cancer Institute: $249,839.00
  • National Cancer Institute: $200,000.00
  • National Cancer Institute: $51,088.00
  • National Cancer Institute: $4,582,303.00
  • National Cancer Institute: $200,000.00
  • National Cancer Institute: $84,897.00
  • National Cancer Institute: $4,798,608.00
  • National Cancer Institute: $4,582,303.00
  • National Cancer Institute: $232,765.00
  • National Cancer Institute: $249,809.00
  • National Cancer Institute: $198,176.00
  • National Cancer Institute: $5,040,816.00
  • National Cancer Institute: $2,669,072.00
  • National Cancer Institute: $12,876.00
  • National Cancer Institute: $100,000.00
  • National Cancer Institute: $100,000.00
  • National Cancer Institute: $107,503.00
  • National Cancer Institute: $140,000.00
  • National Cancer Institute: $100,000.00
  • National Cancer Institute: $167,344.00
  • National Cancer Institute: $249,998.00
  • National Cancer Institute: $89,606.00
  • National Cancer Institute: $1,472,500.00
  • National Cancer Institute: $3,753,703.00
  • National Cancer Institute: $4,444,835.00
  • National Cancer Institute: $198,568.00
  • National Cancer Institute: $245,496.00
  • National Cancer Institute: $10,000.00
  • National Cancer Institute: $2,397,390.00
  • National Cancer Institute: $114,309.00
  • National Cancer Institute: $3,956,712.00
  • National Cancer Institute: $125,000.00
  • National Cancer Institute: $2,449,444.00
  • National Cancer Institute: $134,250.00
  • National Cancer Institute: $49,250.00
  • National Cancer Institute: $5,731,766.00
  • National Cancer Institute: $140,000.00
  • National Cancer Institute: $125,000.00
  • National Cancer Institute: $149,838.00
  • National Cancer Institute: $276,109.00
  • National Cancer Institute: $100,000.00
  • National Cancer Institute: $75,000.00
  • National Cancer Institute: $121,802.00
  • National Cancer Institute: $3,823,791.00
  • National Cancer Institute: $50,569.00
  • National Cancer Institute: $200,000.00
  • National Cancer Institute: $4,284,455.00
  • National Cancer Institute: $50,000.00
  • National Cancer Institute: $2,760,556.00
  • National Cancer Institute: $125,000.00
  • National Cancer Institute: $156,000.00
  • National Cancer Institute: $135,233.00
  • National Cancer Institute: $59,999.00
  • National Cancer Institute: $5,727,388.00
  • National Cancer Institute: $3,716,537.00
  • National Cancer Institute: $498,265.00
  • National Cancer Institute: $276,109.00
  • National Cancer Institute: $10,800.00
  • National Cancer Institute: $5,040,816.00
  • National Cancer Institute: $80,000.00
  • National Cancer Institute: $5,751,010.00
  • National Cancer Institute: $150,000.00
  • National Cancer Institute: $2,516,593.00
  • National Cancer Institute: $85,232.00
  • National Cancer Institute: $3,585,835.00
  • National Cancer Institute: $59,783.00
  • National Cancer Institute: $75,000.00
  • National Cancer Institute: $62,500.00
  • National Cancer Institute: $12,500.00
  • National Cancer Institute: $299,186.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.